Search results for: Oncology
Filter search results
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…medicine (a “follow-on” indication). This represents a hugely important and growing route to new treatment options for many patients, particularly in oncology, immunology, and rare diseases, among others. Adopting policies…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…Cancer, 107, 22-35. DOI | PubMed Doble, B., Tan, M., Harris, A., Lorgelly, P. (2015). Modelling companion diagnostics in economic evaluations of targeted oncology therapies: a systematic review and…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
…grow, adopting OBIs in cancer care represents a strategic opportunity to build on existing benefits of SC drug delivery, and further advance efficiency, sustainability, and patient-centred service delivery across oncology….
OHE at ISPOR Europe: Posters
13 November 2014
…Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014 from Office of Health Economics Koonal Shah and Brendan Mulhern (University of Sheffield) The Expanding Value Footprint of Oncology Treatments. Ispor poster expanding_value_footprint_oncology_treatment_jmf_oct2014 from Office of…
Dr Francois Maignen joins the OHE team as Head of Operational Research and Data Analysis
7 July 2016
…Agency for 15 years. Here he gathered extensive experience in clinical safety and regulation of medicines in the EU (mainly oncology and cardiovascular and similar biological medicinal products in collaboration with…
Aisha Aidarous
17 December 2025
…technology assessment. Her current research interests include economic evaluation of oncology interventions and exploring inequalities in healthcare decision-making and looks forward to expanding her expertise into additional areas of interest….
Patricia Cubi-Molla
4 September 2015
…Health Technology Assessment (HTA), and public-sector resource allocation, including efficiency, inequalities, and priority-setting. She has examined global developments in HTA methods and contributed to studies on decision-making for innovative health technologies, oncology, primary care, climate…
Chris Sampson
9 October 2017
…of clinical contexts, including diabetes, oncology, sleep, and neonatal care, but his passion is for mental health; Chris is the Lead Convener for IHEA’s Mental Health Economics Special Interest Group….
Chris Skedgel
15 July 2019
…He has been a Lead Economic Reviewer for the pan-Canadian Oncology Drug Review (pCODR) and the Canadian Common Drug Review (CDR) and has led the development of NICE submissions in…